AG 10

Drug Profile

AG 10

Alternative Names: AG10; Eidos Therapeutics AG10

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eidos Therapeutics
  • Class Small molecules
  • Mechanism of Action Prealbumin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Amyloidosis

Most Recent Events

  • 28 Sep 2017 Eidos plans clinical trials in Amyloidosis
  • 11 Sep 2017 Phase-I clinical trials in Amyloidosis (In volunteers) in USA (PO) (NCT03294707)
  • 26 Aug 2017 Pharmacodynamics data from preclinical studies in Amyloidosis presented at the Annual Congress of the European Society of Cardiology (ESC-Card-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top